Stock-based Compensation Expense	3 Months Ended
Mar. 28, 2026
Share-Based Payment Arrangement, Noncash Expense [Abstract]
Stock-based Compensation Expense	STOCK-BASED COMPENSATION EXPENSE The Company recognizes compensation expense relating to share-based payments based on the fair value of the equity instrument issued and records such expense in selling and administrative expenses in the Company's consolidated condensed statements of operations. The Company's stock compensation expense was $42 and $101 for the three months ended March 28, 2026 and March 29, 2025, respectively. On March 12, 2026, the Company issued 247,458 shares of restricted stock to certain key employees. The grant-date fair value of the awards was $105, or $0.425 per share, and is expected to be recognized as stock compensation expense over a weighted-average period of 5.7 year from the date the awards were granted. Each award is subject to a continued service condition. The fair value of each restricted stock awarded was equal to the market value of a share of the Company's Common Stock on the grant date.

Stock-based Compensation Expense

3 Months Ended

Mar. 28, 2026

Share-Based Payment Arrangement, Noncash Expense [Abstract]

STOCK-BASED COMPENSATION EXPENSE

The Company recognizes compensation expense relating to share-based payments based on the fair value of the equity instrument issued and records such expense in selling and administrative expenses in the Company's consolidated condensed statements of operations. The Company's stock compensation expense was $42 and $101 for the three months ended March 28, 2026 and March 29, 2025, respectively.

On March 12, 2026, the Company issued 247,458 shares of restricted stock to certain key employees. The grant-date fair value of the awards was $105, or $0.425 per share, and is expected to be recognized as stock compensation expense over a weighted-average period of 5.7 year from the date the awards were granted. Each award is subject to a continued service condition. The fair value of each restricted stock awarded was equal to the market value of a share of the Company's Common Stock on the grant date.